The European Molecular Genetics Quality Network, a provider of proficiency testing services for clinical genetics and molecular pathology labs, and its UK partner have been developing a new assessment scheme for NGS labs.
The company presented its findings last week at the 2016 Gastrointestinal Cancer Symposium and is preparing to launch the assay in the US later this year.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The company demonstrated high analytical sensitivity and specificity, and also showed clinical data supporting a high concordance with tumor tissue sequencing.
The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.
The 3M Molecular Detection Assay 2 – Listeria monocytogenes is 30 percent faster than the first-generation test.
The company completed analytical validation of MetaSite Breast, and is planning to complete three additional studies before launching it on the market with MenaCalc.
Quest offers its BRCAvantage test on the MiSeq, has other oncology and neurology NGS tests in development, and is converting all its Sanger tests to NGS.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.